Mutated Pkhd1 alone is sufficient to cause autoimmune biliary disease on the nonobese diabetic (NOD) genetic background

David E. Adams1,2 · Luke S. Heuer4,5 · Manuel Rojas3,5 · Weici Zhang4,5 · William M. Ridgway4,5

Received: 7 July 2022 / Accepted: 27 August 2022 / Published online: 13 September 2022
© The Author(s) 2022

Abstract
We previously reported that nonobese diabetic (NOD) congenic mice (NOD.c3c4 mice) developed an autoimmune biliary disease (ABD) with similarities to human primary biliary cholangitis (PBC), including anti-mitochondrial antibodies and organ-specific biliary lymphocytic infiltrates. We narrowed the possible contributory regions in a novel NOD.Abds congenic mouse to a B10 congenic region on chromosome 1 (“Abd3”) and a mutated Pkhd1 gene (Pkhd1del36−67) upstream from Abd3, and we showed via backcrossing studies that the NOD genetic background was necessary for disease. Here, we show that NOD.Abds mice develop anti-PDC-E2 autoantibodies at high levels, and that placing the chromosome 1 interval onto a scid background eliminates disease, demonstrating the critical role of the adaptive immune system in pathogenesis. While the NOD genetic background is essential for disease, it was still unclear which of the two regions in the Abd3 locus were necessary and sufficient for disease. Here, using a classic recombinant breeding approach, we prove that the mutated Pkhd1del36−67 alone, on the NOD background, causes ABD. Further characterization of the mutant sequence demonstrated that the Pkhd1 gene is disrupted by an ETnII-beta retrotransposon inserted in intron 35 in an anti-sense orientation. Homozygous Pkhd1 mutations significantly affect viability, with the offspring skewed away from a Mendelian distribution towards NOD Pkhd1 homozygous or heterozygous genotypes. Cell-specific abnormalities, on a susceptible genetic background, can therefore induce an organ-specific autoimmunity directed to the affected cells. Future work will aim to characterize how mutant Pkhd1 can cause such an autoimmune response.

Keywords NOD · Pkhd1 · Autoimmunity · Primary biliary cholangitis (PBC)

Introduction

Primary biliary cholangitis (PBC) is an incurable autoimmune disease characterized by highly specific antimitochondrial autoantibodies (AMAs) and autoimmunity directed to cholangiocytes, with progressive destruction of intrahepatic bile ducts. Some progress has been made in understanding human PBC, including identifying the target mitochondrial autoantigens which induce the characteristic anti-pyruvate dehydrogenase complex (anti-PDC-E2) autoantibodies, mapping the T and B cell autoantigenic epitopes, and defining mechanisms of tissue destruction (Lleo et al. 2020). We serendipitously discovered a model of PBC while studying type 1 diabetes (T1D) in nonobese diabetic (NOD) mice (Irie et al. 2006a, b; Koarada et al. 2004). We found that NOD congenic mice with B6/B10 regions inserted onto the NOD background (strain NOD.c3c4) were protected from diabetes but developed a spontaneous autoimmune biliary disease. Lymphoid cell infiltrates in these mice specifically
targeted the biliary epithelium, not the hepatic parenchyma, and demonstrated classic histological lesions of PBC including granulomas, peri-biliary lymphocytic infiltration, and nonsuppurative destructive cholangitis (NSDC), considered highly characteristic of PBC. Importantly, there was a highly specific immune signature identical between NOD.c3c4 mice and human PBC: the strain was the first ever to spontaneously develop anti-PDC-E2 antibodies, the hallmark of human PBC (Irie et al. 2006a, b). The NOD.c3c4 model thus bore many remarkable similarities to human PBC although, like most mouse models, this model has some differences from human PBC. Therefore, we term the model “autoimmune biliary disease” (ABD). However, the presence of anti-PDC-E2 antibodies, the characteristic immunopathological lesions, and the involvement of the immune system are strong reasons to use these mice to model pathogenic events in PBC.

We used a mouse congenic approach to study the immunogenetic causes of NOD ABD (Wicker et al. 1995). We developed a large number of congenic mice, termed “NOD.ABD” mice overall, with the initial goal of narrowing the congenic chromosome 3 and 4 intervals to find causative genes. During this process, a 5 k SNP chip detected a heretofore unrecognized region on chromosome 1 in all the NOD.ABD strains that developed disease; we designated this region Abd3 (Yang et al. 2011). Subsequently, we made a congenic mouse (“NOD.Abd3”) expressing only the Abd3 region on the NOD background and showed that this c1 region is necessary and sufficient for disease. We made a major breakthrough in understanding how this region causes disease, using RNA-seq to show that Pkhd1 (Polycystic Kidney and Hepatic Disease 1), which is upstream on chromosome 1, is mutated in NOD.Abd3 mice with truncation after Abd3 some 1, is mutated in NOD.ABD strains that developed disease; we designated this region Abd3 (Yang et al. 2011). Subsequently, we made a congenic mouse (“NOD.Abd3”) expressing only the Abd3 region on the NOD background and showed that this c1 region is necessary and sufficient for disease. We made a major breakthrough in understanding how this region causes disease, using RNA-seq to show that Pkhd1 (Polycystic Kidney and Hepatic Disease 1), which is upstream on chromosome 1, is mutated in NOD.Abd3 mice with truncation after exon 35 (designated “Pkhd1del36-67”) (Huang et al. 2018). Pkhd1 encodes fibrocystin, a large protein that is expressed in primary cilia including cholangiocyte cilia (Nagasawa et al. 2002; Ward et al. 2003). Mutations in Pkhd1 can result in either renal, pancreatic, or biliary disease, manifested by cyst formation (Gallagher et al. 2008; Moser et al. 2005; Williams et al. 2008). Some Pkhd1 mutations, including Pkhd1del36-67 and Pkhd1del44/del4, however, result in liver-specific disease; in the Pkhd1del44/del4 model, this disease was ameliorated by macrophage depletion, showing a role of the immune system in pathogenesis (Locatelli et al. 2016). In the NOD.Abd3 mice, the NOD genetic background was essential for the disease; in addition, adaptive immunity was necessary (since NOD.c3c4-scid mice did not develop clinical disease) (Huang et al. 2018). However, it was still unclear which genetic regions in the Abd3 interval contributed to the disease: The B6 congenic interval (termed “B6-Abd3”) could play a role in conjunction with Pkhd1del36-67 to mediate autoimmunity in this model. Herein, we show that the NOD.Abd3 mouse, like the original NOD.c3c4 mouse, develops high levels of the PBC-specific anti-PDC-E2 autoantibodies. In addition, we show that NOD.Abd3 mice require an adaptive immune system to develop the disease. Finally, using a classic recombinant breeding approach, we prove that the mutated Pkhd1del36-67 alone, on the NOD background, causes ABD in this strain. Cell-specific abnormalities (in this case, aberrant Pkhd1 expression in cholangiocytes) on a susceptible genetic background can therefore induce an organ-specific autoimmunity directed to the affected cells.

### Materials and methods

#### Processing of tissues for PCR

Genomic DNA from NOD and NOD.Abd3-derived tissues (e.g., ear, tail) was prepared using QIAGEN’s DNeasy Blood & Tissue kit. The isolated DNAs were stored at –20 °C until use. The DNA primers used for genotyping of the NOD and NOD.Abd3 mice and offspring were designed using either Primer3 or PCRTiler v1.42 software. The DNA primers were purchased from Sigma-Aldrich.

#### Abd3 PCR

To distinguish between the NOD and NOD.Abd3 alleles, both PCR amplification and restriction digestion are required. The sequences of the four primers used for Abd3 genotyping are the following:

| Name                  | Sequence               | PCR products |
|-----------------------|------------------------|--------------|
| rs32160775-F          | 5′ AGATTCGCGTGTGGAGTCA 3′ | 3′           |
| rs32160775-R          | 5′ CGACTTCCTCAAGTGTCAT 3′ | 5′           |
| rs36742082-F          | 5′ AAGGCGAATTGCTCAAGGT 3′ | 3′           |
| rs36742082-R          | 5′ TCTGAGGTTGATCTGGAA 3′  | 5′           |

A DNA Engine Thermal Cycler (MJ Research) was used for PCR amplification. The program used included the following steps:

| Step | Temperature | Time (min) |
|------|-------------|------------|
| 1    | 95 °C       | 15:00      |
| 2    | 95 °C       | 0:10       |
| 3    | 55 °C       | 0:30       |
| 4    | 72 °C       | 0:30       |
| 5    | 72 °C       | 35 times   |
| 6    | 4 °C        | 0:00       |

*Denature* (i.e., 15 min)*

*i.e., denature for 10 s*

*i.e., anneal for 30 s*

*i.e., extend for 30 s*

*i.e., cycle 35 times*

*i.e., 5 min final extension*

*i.e., 4 °C indefinite*
AmpliTaq Gold DNA polymerase (Applied Biosystems, Cat. No. N808-0241) was purchased to amplify the genomic DNA. This polymerase is supplied in an inactive state and must be activated by heat, either before or during PCR cycling. *Step 1 of the PCR protocol accomplishes this. After DNA amplification, the individual PCR products were divided in two, and one half of each of the 112-bp rs32160775 amplification products was restricted with BsmAI at 55 °C for 1 h, while half of each of the 121-bp rs36742082 products was restricted with BsmAI, while the NOD.Abd3 products are not. The NOD.Abd3 rs36742082 products are cleaved by BsmAI, while the NOD products are not. The two sets of reactions and PCRs thus give complimentary genotyping data. The final DNA products were run on a 3.0% agarose gel to distinguish the DNA products based on their size. Restriction endonucleases were purchased from New England BioLabs and UltraPure™ Agarose from Invitrogen (Cat. No. 16500-100). The electrophoresed DNAs were stained using 0.05 μg/ml ethidium bromide for 30 min, then the gels rinsed with water to remove background staining, and the PCR products visualized by high-intensity, 302-nm UV light photography using a Cell Biosciences, Inc.’s FluorChem HD2 gel doc system with AlphaView version 3.2.2.0 software. Gel images were opened in Adobe Photoshop CC 2018 and exported to PowerPoint 2016 for processing.

**Pkhd1 PCR**

The sequences of the four primers used to genotype the NOD and NOD.Abd3 Pkhd1 alleles are as follows:

| Name  | Sequence                  |
|-------|---------------------------|
| P7f   | 5′TGGATAACCTCATCCCTCTTTAAA3′ |
| P1r   | 5′TGTTAGCCACAGATGGCTTT3′   |
| P2f   | 5′AACCCCTAATTCCCAGGTCA3′   |
| P2r   | 5′TGAGCAGTGCAGCTATGA3′     |

The Pkhd1 allele PCR amplification program used was the same as that used for the Abd3 PCR. After cycling program was finished, the amplified PCR products were run on a 2.0% agarose gel to distinguish the products based on their size. The “wild type” NOD Pkhd1 intron 35 P2f+P2r PCR yields a 313-bp product, while the “mutant” NOD.Abd3 Pkhd1 intron 35 P7f+P1r PCR yields a 379-bp product. Occasionally, additional amplification products are seen, especially using the P7f+P1r primers, but the source of these larger ~700-bp DNA products is unknown.

**Identification of ETnII-beta retrotransposon integrant in the NOD.Abd3 Pkhd1 allele**

A retrotransposon integrant in the NOD.Abd3 Pkhd1 allele was originally identified by (Huang et al. 2018). Further characterization of the integrant and its PCR genotyping were performed here. Node-1, node-2, and node-3 sequences (see Fig. 8E (Huang et al. 2018)) originally obtained by sequencing the NOD and NOD.Abd3 mice Chr. 1 Pkhd1 intron 35 regions were entered into BLASTn. Extensive homology of the node sequences was found to the 5541-bp Mus musculus retrotransposon ETnII-beta, complete sequence (GenBank: KC12757.1). These five sequences, i.e., the complete ETnII-beta sequence, the relevant NOD Pkhd1 intron 35 region, and the NOD.Abd3 Pkhd1 node-1, node-2, and node-3 regions, were then entered into the CLUSTAL O (1.2.4) alignment program, and the resulting alignment further refined by visual analysis. Two CTTTCC repeats were identified that flank the integrated ETnII sequence in the NOD.Abd3 Pkhd1 intron 35 mutant allele, with a single CTTTCC site in the original NOD sequence marking the retrotransposon integration site. Except for a single TT pair located at position 2996–97 in the KC12757.1 sequence and missing in the mutant Pkhd1 sequence, and an extra TT pair present in the mutant Pkhd1 sequence at position 5200 in the PubMed ETnII sequence, the ETnII-beta integrant in the mutant Pkhd1 intron 35 is essentially complete. Binding sites for the Pkhd1 genotyping primers P2r, P1r, P7f, and P2f were identified in the NOD.Abd3 Pkhd1 sequence with the predicted products of PCR agreeing with what was observed (see gel figures and mutant allele diagram).

**Animal husbandry and histological scoring**

Animals were housed in the Cincinnati VA Animal facility and provided food and water ad libitum. Regular feeding chow was used, even for breeder pairs. Tissue samples, obtained from either the ear or tail, were typically taken when the pups were weaned at 3 weeks of age and again at sacrifice. The mice were observed for phenotype from birth and processed for histology between 4 and 5 months of age, unless they showed signs of liver disease earlier. Mice for breeding pairs were identified by PCR to separate the closely linked NOD- and NOD.Abd-3-derived Pkhd1 and Abd3 alleles. Liver samples for histology were stored in fixative (10% buffered formalin, Fisher Health Care) until embedded in paraffin, sectioned for H&E staining, and digitally imaged by the Cincinnati Children’s (CCHMC) Pathology Research Core. At the time of sacrifice, liver appearance and common biliary duct (CBD) diameter were scored for the NOD- and NOD.Abd3-derived animals. Liver sections were
scored for biliary disease using the following scale: (0) No bile duct disease; (1) Mild bile duct disease: at least 25% of bile ducts affected by inflammatory infiltrates; (2) Moderate bile duct disease: at least 50% of bile ducts affected; (3) Severe bile duct disease: at least 75% of bile ducts affected. Gross pathology of the liver was scored as follows: “0” normal; “1” very few lesions in the liver detectable; “2” lesions in liver easily noticed; “3” many liver lesions easily seen; “4” many lesions in most or all lobes; “5” liver completely full of lesions.

**Results**

The original NOD.c3c4 mouse had multiple B6/B10 congenic intervals that had a profound effect on NOD immunity: these regions completely suppressed development of type 1 diabetes in this strain (Irie et al. 2006a, b; Koarada et al. 2004). In particular, the Idd9.3 region was responsible for development of autoantibodies such as ANAs and anti-Smith autoantibodies (Irie et al. 2006). We therefore tested whether NOD.Abd3 mice developed the signature anti-PDC-E2 autoantibodies found in the NOD.c3c4 strain, despite lacking the c3 and c4 congenic regions. As shown in Fig. 1, NOD.Abd3 mice developed high titers of anti-PDC-E2 autoantibodies. Common bile duct (CBD) dilation is a pathological marker of clinical disease development in these mice (Irie et al. 2006a, b; Koarada et al. 2004), and NOD.Abd3 mice without CBD dilation had significantly lower anti-PDC-E2 antibody levels (Fig. 1a). Increased CBD size correlates with worse disease (Irie et al. 2006a, b; Koarada et al. 2004), and anti-PDC-E2 antibody levels significantly correlate with CBD size (Fig. 1b). Likewise, NOD.Abd3 mice develop comparable CBD diameter dilation to NOD.c3c4 mice (Fig. 2b) and gross pathological abnormalities in the liver as measured by cyst burden (Fig. 2C). Furthermore, we have previously shown that the adaptive immune system was necessary for ABD, since NOD.c3c4-scid mice did not develop clinical disease, but only minor histological abnormalities (Huang et al. 2018; Irie et al. 2006a, b; Yang et al. 2011). We next confirmed that mice expressing only the Abd3 region on the NOD background did not develop clinical disease when the scid mutation was introduced (Fig. 2). Thus, the Abd3 region alone was sufficient to develop biliary autoimmunity and PBC autoantibodies on the NOD background. The major features of autoimmune biliary disease were therefore found to remain in this strain with only the minimal Abd3 congenic interval. However, it was still unclear whether the B6-Abd3 region, the mutated Pkhdl region, or both were necessary for disease.

Recombinant mice were generated as described (see “Materials and methods”), and mice were bred by further backcrossing to generate mice that were heterozygous or homozygous for Pkhdlmutmut and which lacked the B6-Abd3 congenic interval. Generation of PCR primers to detect the Pkhdlmutmut mutation revealed that the ETnII-beta retrotransposon causing the mutation is inserted into the Pkhdl gene in the antisense orientation (“Materials and methods”, Fig. 3), which has possible implications for pathological effects (see “Discussion”). Fifty-five F4 and twenty-one F5 mice were

---

Generation of recombinant mice and breeding Pkhdlmutmut homozygosity

NOD and NOD.Abd3 mice were bred to generate F1 mice, which were crossed to generate F2 mice. F2 mice were screened to identify recombinant mice (between the Abd3 and Pkhdl loci), which were either homozygous for the NOD Abd3 allele (i.e., were not congenic in the Abd3 region) but heterozygous at Pkhdl, or heterozygous at the Abd3 locus but homozygous for Pkhdlmut (either genotype indicated a recombinant event between the loci). Four recombinant mice (3 males and 1 female) were identified out of 73 genotyped F2 mice. The recombinant male F2 breeders were backcrossed to NOD mice to produce F3 mice that were homozygous for NOD Abd3 and heterozygous at Pkhdl. These were intercrossed to produce F4 mice that were genotyped and phenotyped to detect mice with homozygosity for Pkhdlmut. Additional F5 mice were generated by F4 intercrosses and also genotyped/phenotyped.

Detection of serum AMA levels

Recombinant pyruvate dehydrogenase complex-E2 (PDC-E2) protein was used to detect serum levels of anti-mitochondrial antibodies by enzyme-linked immunosorbent assay (ELISA) using well-established protocols from our laboratory (Bae et al. 2016; Tsuda et al. 2013). PDC-E2 recombinant protein at a concentration of 5 μg/ml in carbonate buffer (pH 9.6) was coated on 96-well ELISA plates at 4 °C overnight. Plates were then washed 3 × with phosphate-buffered saline Tween-20 (PBS-T 0.05%) prior to incubation with a blocking solution for 1 h at RT. TMB substrate (BD Biosciences, San Jose, CA) was then added to wells, incubated for 15 min at RT, and then read at OD450nm on a microplate reader. Control serum samples for both positive and negative AMA levels were included on each plate.
generated (Table 1). Of these, the NOD (wild type) Pkhd1 and heterozygous mice were in numbers as expected by a Mendelian distribution; however, the number of Pkhd1del36−67 homozygous mice was significantly reduced (Table 1), which might reflect decreased viability (see “Discussion”). Figure 4a shows two littermates; the mouse with homozygous Pkh-d1del36 demonstrates the characteristic findings of biliary epithelial proliferation with immune cell infiltrates adjacent to cholangiocytes (Fig. 4a), identical to the histological picture in NOD.c3c4 and NOD.ABD mice as previously described (Irie et al. 2006a, b; Koarada et al. 2004; Yang et al. 2011) and as shown in Fig. 2a. The offspring with wild-type Pkhd1 displayed no abnormalities (Fig. 4a). Blinded scoring of the histology in these mice very clearly showed that ABD is present in mice lacking the B6-Abd3 congenic interval but only in mice with two copies of Pkhd1del36−67 (Fig. 4). This result proves definitively that the Pkhd1del36−67 mutation is the only genetic component in the Abd3 region necessary to promote ABD on the NOD genetic background.

**Discussion**

The NOD mouse is best known as a model of spontaneous T1D; however, they develop multiple other spontaneous autoimmune conditions such as thyroiditis and Sjögren’s syndrome. Immunogenetic components contributory to NOD autoimmune disease include the TCR-MHC interaction (signal 1), co-stimulatory molecules (signal 2), and cytokines (signal 3) as reviewed by Aubin et al. (Aubin et al. 2022). The NOD immunogenetic background is susceptible to autoimmunity and to understand the basis of this heightened immunity, congenic mapping experiments were conducted to identify genetic regions responsible for the diabetes phenotype. This approach identified multiple genes and genetic regions (over 50 Idd regions to date (Driver et al. 2012)). The autoimmune biliary disease (ABD) phenotype emerged during congenic experiments designed to completely eliminate T1D by introgressing large congenic regions from chromosomes 3 and 4 onto the NOD background (the NOD.c3c4 mice). Initially, this was a perplexing result as it was unclear how introducing non-NOD alleles could protect against diabetes but simultaneously cause the NOD mouse to switch to autoimmune liver specificity (Ridgway 2006). The original hypothesis was that immune-related genes within the chromosome 3 or 4 region might control organ specificity. However, we subsequently discovered a small non-NOD genetic region on chromosome 1 that was present in all strains afflicted with disease (Huang et al. 2018). Further investigation using RNAseq found that the mRNA of a non-immune-related gene Pkhd1 had been truncated by a retrotransposon insertion. To ensure that the non-NOD B6-Abd3 region was not responsible for the autoimmune phenotype, herein we created recombinant mice lacking the B6-Abd3 region and only expressing the mutated Pkhd1 on the NOD background. Therefore, for the first time, we have shown that a non-immune, tissue-specific mutation on the hyperimmune NOD background can promote an organ-specific autoimmune disease.

The Pkhd1 gene encodes fibrocystin/polyductin, a large single-membrane spanning protein of unknown function (Bergmann 2018). It is widely expressed during fetal development and thought to be involved in tubular morphogenesis. In adulthood, expression is localized to apical...
membranes and the primary cilia of epithelial cells in the kidney, liver, and pancreas (Zhang et al. 2004). Aberrant expression during fetal development and its involvement in tubule morphogenesis may explain the deficiency we observe in the number of homozygous mutant pups in Table 1. Alternatively, early transposon (ETn) elements are transcribed during early mouse embryogenesis in embryonic stem (ES) and embryonic carcinoma (EC) cell lines (Maksakova and Mager 2005). Formation of an RNA:RNA hybrid between the (reverse transcribed) ETn-Pkhdl1 insert and the (forward transcribed) mutant Pkhdl1 mRNA (with the retroviral insert in intron 35) could occur during mouse embryogenesis in the mutant Pkhdl1 mouse. This could play a role in the NOD.Abd3 model and in poor survival of neonatal homozygotes. While fibrocystin’s exact function is unknown, it is thought to interact with other receptors (polycystins) on epithelial cilia that participate in sensing of bile flow (Kim et al. 2008a, b; Olson et al. 2019). In the polycystins) on epithelial cilia that participate in sensing of bile flow (Kim et al. 2008a, b; Olson et al. 2019). In the presence of adaptive immune cells; 4×magnification).

B) Dilation of the common bile duct (in mm) in NOD.Abd3 and NOD.c3c4 with significant reduction in the absence of adaptive immunity (scid). C) Gross liver pathology scoring of disease in NOD.Abd3 and NOD.c3c4 with significant reduction on a scid background. *p < 0.01, **p < 0.001 by Kruskal–Wallis with Dun’s post hoc test. NOD.Abd3 (n = 12), NOD.Abd3-scid (n = 16), NOD.c3c4 (n = 12), NOD.c3c4-scid (n = 14)

In addition to the PCK rat, several mouse models of Pkhdl1 gene disruption have been produced to model human autosomal recessive polycystic kidney disease (ARPKD) and congenital hepatic fibrosis (CHF). These include Pkhdl1lacZ/lacZ (exon 1–3) (Williams et al. 2008), Pkhdl1del2del2 (exon 2) (Woollard et al. 2007), Pkhdl1ex40 (exon 40) (Moser et al. 2005), Pkhdl1del3–4del3–4 (exon 3–4) (Garcia-Gonzalez et al. 2007), Pkhdl1del4del4 (exon 4) (Gallagher et al. 2008), Pkhdl1C642*/C642* (exon 20) (Shan et al. 2019), Pkhdl1LSL(−)/LSL(−) (exon 3) (Bakeberg et al. 2011), and Pkhdl1LSLΔ15/GFPΔ15 (exon 15–16) (Kim et al. 2008a, b). Depending on the site of the Pkhdl1 gene disruption and the genetic background of the mouse, the affected tissue and severity can vary tremendously. For example, the Pkhdl1lacZ/lacZ, Pkhdl1del3–4del3–4, Pkhdl1C642*/C642*, Pkhdl1Δ15/GFPΔ15, and Pkhdl1/− all develop renal cysts whereas Pkhdl1ex40 and Pkhdl1del4del4 do not. Interestingly, when the Pkhdl1del2del2 strain was inbred back to either C57BL/6 J or BALBc/J, cysts developed much earlier in life and disease was more severe. Pancreatic cysts of varying severity are also found in all but the Pkhdl1ex40 and Pkhdl1del4del4 strains. The Pkhdl1Δ15/GFPΔ15 strain was reported to occasionally develop brain cysts and abnormal ulcers in the gastrointestinal tract. The most consistent pathologic feature is cyst development of the intrahepatic bile ducts along with fibrosis of the periportal tract.

The most striking difference between these eight models and our NOD Pkhdl1 mutant model is that, prior to the Locatelli paper in 2016, none of these models described immune infiltrates, whereas immune infiltration is a major component of our model. Gallagher et al. studied the same Pkhdl1del4del4 model as Locatelli, but did not describe infiltrates.

---

**Fig. 2** NOD.Abd3 mice lacking the B6.c3c4 congenic intervals present with the same histopathological abnormalities as the NOD.c3c4 strain. A H+E stained liver sections from 120- to 130-day NOD.Abd3 and NOD.c3c4 (left) with respective scid mutations (right) showing comparable histology and lack thereof in the absence of adaptive immune cells; 4×magnification. B) Dilation of the common bile duct (in mm) in NOD.Abd3 and NOD.c3c4 with significant reduction in the absence of adaptive immunity (scid). C) Gross liver pathology scoring of disease in NOD.Abd3 and NOD.c3c4 with significant reduction on a scid background. *p < 0.01, **p < 0.001 by Kruskal–Wallis with Dun’s post hoc test. NOD.Abd3 (n = 12), NOD.Abd3-scid (n = 16), NOD.c3c4 (n = 12), NOD.c3c4-scid (n = 14)

---

**Table 1** Genotype distribution of NOD vs. mutated Pkhdl1. Expected numbers according to a Mendelian distribution are in parentheses

|          | NOD Pkhdl1 | Heterozygous | Mutated Pkhdl1 |
|----------|------------|--------------|----------------|
| F4       | 15 (14)    | 34 (28)      | 6 (14)         |
| F5       | 7 (5)      | 12 (11)      | 2 (5)          |

---

**Fig. 3** Schematic of retrotransposon insertion site into intron 35 of Pkhdl1. The ETnII-beta retrotransposon in the NOD.Abd3 mouse is inserted into the Pkhdl1 gene in the antisense orientation.
A. NOD Pkhd1 vs NOD Pkhd1del36-67

B. Disease Severity

| Pkhd1 Genotype       | Severe | Moderate | Mild | None |
|----------------------|--------|----------|------|------|
| Pkhd1del36-67 Homozygous | 6      | 3        | 0    | 0    |
| Heterozygous         | 0      | 0        | 5    | 30   |
| Pkhd1 Homozygous     | 0      | 0        | 1    | 28   |
The pathological role of the immune system in cystic/fibrotic liver disease has thus been recognized only very recently. Locatelli et al. showed that the immune system is involved in perpetuating cysts/fibrosis in the Pkhd1 del4/del4 mouse on the C57BL/6 background (Locatelli et al. 2016). In their model, on the non-autoimmune B6 background, dysfunctional fibrocystin causes an immune infiltrate composed largely of macrophages, resulting in upregulation of chemokines and skewing to an M2 phenotype that promotes cyst formation and peribiliary fibrosis. Elimination of macrophages by clodronate liposomes prevents this pathology, indicating that the underlying Pkhd1 del4/del4 mutation can initiate a damage response, but that the innate immune response to tissue stress ultimately drives the disease. In our model, in contrast to all other models, immune infiltrates are a major component of the disease, and are not limited to macrophages but include adaptive immune cells. In our model on the autoimmune NOD background, suppression of the adaptive immune system by either irradiation (Koarada et al. 2004), anti-CD3 antibodies, or introduction of the scid mutation eliminated clinical disease and resulted in only minor, subclinical duct abnormalities (Irie et al. 2006a, b). While both our model and the Pkhd1 del4/del4 model show a critical role for the immune system, another major difference between them is the time course of disease. In the Pkhd1 del4/del4 model, disease progresses slowly, with immune infiltration at 6 months of age and mice surviving past 12 months. Our NOD Pkhd1 models on the autoimmune-prone NOD background on the other hand develop immune infiltration by 10 weeks and the disease is often fatal by 4 months. The adaptive immune system drives this accelerated pathology via involvement of autoreactive T and B cells on the NOD background. We have previously shown that adoptive transfer of splenocytes or CD8-positive T cells alone can drive the disease (Irie et al. 2006a, b; Koarada et al. 2004; Yang et al. 2011). In addition, these mice develop class switched anti-PDC-E2 autoantibodies, indicating that T helper cells are actively driving the immune response. In our NOD models, macrophages infiltrate the lesions and undoubtedly also play a role in disease pathology, but with the addition of autoreactive T cell help, they can be fully licensed to maximize effector function. In this case, not only do we observe accelerated cyst formation but we also find non-suppurative destructive cholangitis, epithelioid granulomas, and anti-PDC-E2 antibodies that are hallmarks of PBC. In the current study, we show that the liver disease and immune infiltrates are both fully present in the NOD Pkhd1 del36−67 mice lacking the B10 Ab3 genetic region. While we have not tested this strain for anti-PDC-E2 antibodies, all the evidence suggests the NOD background drives the autoimmune component including the broad immune infiltrates seen here. However, it remains possible that the Ab3 region contributes to antibody formation and this has not been formally excluded, which is a limitation of our study. In contrast, the Pkhd1 del4/del4 mutation on the C57BL6 background presumably lacks autoreactive T cells and dysfunctional fibrocystin results in a classic tissue damage response from innate immune cells resulting in slowly progressive fibrosis. While both models lack a functional fibrocystin and presumably have similar tissue stress, the differing immune system response to that stress/damage controls the pathological outcome.

We have shown that the Pkhd1 del36−67 mutation alone is the initiating factor in the observed cholangiocyte pathology. How this single mutation leads to PBC-like autoimmunity is important since the mechanism for breaking tolerance to PDC-E2 and the initiation of PBC is poorly understood. One potential mechanism is that changes in cilia structure or how the cholangiocyte senses and reacts to bile acids may lead to cellular damage and presentation of PDC-E2 to T cells (Kim et al. 2008a, b). Additionally, alterations in bile acid composition or flow can modulate microbiome composition and/or enhance susceptibility to infections via the gut. Infec-

tions, and Escherichia coli in particular, have been implicated in PBC etiology, likely by inducing molecular mimicry between microbial PDC-E2 and human PDC-E2 (Yang et al. 2022). Finally, the antisense insertion of a retrotransposon as the mutagenic factor may have immune-stimulating properties. Expression of the antisense retrotransposon can lead to dsRNA, a potent stimulator of an antiviral type I IFN response which, if chronically activated, can enhance autoimmune diseases (Gazquez-Gutierrez et al. 2021). In addition, early transcription of the ETnII insert during embryogenesis may help accelerate development of disease. The NOD.Abd3 mouse therefore presents a compelling model in which to study the initiation of PDC-E2-mediated autoimmunity to better understand the pathogenesis of human PBC.

Acknowledgements This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development, project number IO1BX003821-01A1.

Author contribution D.E.A., L.S.H., M.R., and W.Z. performed experiments, analyzed data, created figures, and wrote up the results. D.E.A., L.S.H., and W.M.R. planned the experiments, analyzed data, and wrote the manuscript. W.M.R. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Springer
Declarations

Ethical approval All animal procedures were conducted according to approved protocols of the University of Cincinnati College of Medicine or the Merck Research Laboratories Animal Care and Use Committees.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Aubin A-M, Lombard-Vadnais F, Collin R, Aliesky HA, McLachlan SM, Lesage S (2022) The NOD mouse beyond autoimmune diabetes. Front Immunol. https://doi.org/10.3389/fimmu.2022.874769

Bae HR, Leung PS, Tsuneyama K, Valencia JC, Hodge DL, Kim S, Aubin A-M, Lombard-Vadnais F, Collin R, Aliesky HA, McLachlan SM, Lesage S (2022) A novel Pkhd1 mutation interacts with the nonobese diabetic genetic background to cause autoimmune cholangitis. J Immunol 200(1):147–162. https://doi.org/10.4049/jimmunol.1701087

Irie J, Wu Y, Siss DA, Ridgway WM (2006a) Genetic control of anti-Sm autoantibody production in NOD congenic mice narrowed to the Idd9.3 region. Immunogenetics 58(1):9–14. https://doi.org/10.1007/s00251-005-0066-1

Irie J, Wu Y, Wicker LS, Rainbow D, Nalesnik MA, Hirsch R, Ridgway WM (2006b) NOD.c3-c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med 203(5):1209–1219. https://doi.org/10.1084/jem.20051911

Kim I, Fu Y, Hui K, Moeckel G, Mai W, Li C, Wu G (2008a) Fibrocystin/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function. J Am Soc Nephrol 19(3):455–468. https://doi.org/10.1681/asn.2007070770

Kim I, Li C, Liang D, Chen XZ, Colly RJ, Ma J, Wu G (2008b) Polycystin-2 expression is regulated by a PC2-binding domain in the intracellular portion of fibrocystin. J Biol Chem 283(46):31559–31566. https://doi.org/10.1074/jbc.M805452200

Koarada S, Wu Y, Fertig N, Siss DA, Nalesnik M, Todd JA, Ridgway WM (2004) Genetic control of autoimmunity: protection from diabetes, but spontaneous autoimmune biliary disease in a nonobese diabetic congenic strain. J Immunol 173(4):2315–2323. Retrieved from http://jimmunol.org/content/173/4/2315.abstract

Lleo A, Wang GQ, Gershwin ME, Hirschfield GM (2020) Primary biliary cholangitis. Lancet 396(10266):1915–1926. https://doi.org/10.1016/S0140-6736(20)31607-X

Locatelli L, Cadamuro M, Spiri C, Fiorotto R, Lecchi S, Morell CM, Strazzabosco M (2016) Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. Hepatology 63(3):965–982. https://doi.org/10.1002/hep.28382

Maksakova IA, Mager DL (2005) Transcriptional regulation of early transposon elements, an active family of mouse long terminal repeat retrotransposons. J Virol 79(22):13865–13874. https://doi.org/10.1128/JVI.79.22.13865-13874.2005

Masyuk TV, Huang BQ, Ward CJ (2003) Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. Gastroenterology 125:1303–1310. Retrieved from https://doi.org/10.1016/j.gastro.2003.09.001

Moser M, Matthiesen S, Kirfel J, Schorle H, Bergmann C, Senderek J, Buettner R (2005) A mouse model for cystic biliary dysgenesis in autosomal recessive polycystic kidney disease (ARPKD). Hepatology 41(5):1113–1121. https://doi.org/10.1002/hep.20655

Nagasawa Y, Matthiesen S, Onuchic LF, Hou X, Bergmann C, Esquivel E, Germoing G (2002) Identification and characterization of Pfhd1, the mouse orthologue of the human ARPKD gene. J Am Soc Nephrol 13(9):2246–2258. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12191969

Olson RJ, Hopp K, Wells H, Smith JM, Furtado J, Constans MM, Harris PC (2019) Synergistic genetic interactions between pkhd1 and pkdl1 result in an arpkd-like phenotype in murine models. J Am Soc Nephrol 30(11):2113–2127. https://doi.org/10.1681/ASN.2019020150

Ridgway WM (2006) Dissecting genetic control of autoimmunity in NOD congenic mice. Immunol Res 36(1–3):189–196. https://doi.org/10.1385/ir:36:1:189

Shan D, Rezonzew G, Mullen S, Roye R, Zhou J, Chunley P, Mrug L, Ridgway WM, Li C, Wu G (2019) Heterozygous Pkhd1C642* mice develop cystic liver disease and proximal tubule ectasia that mimics radiographic signs of medullary sponge kidney. Am J Physiol Renal Physiol 316(3):F463–F472. https://doi.org/10.1152/ajprenal.00181.2018

Tsuda M, Zhang W, Yang G-X, Tsuneyama K, Ando Y, Kawata K, Gershwin ME (2013) Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice. Hepatology 57(2):806–816. https://doi.org/10.1002/hep.25829

Ward CJ, Yuan D, Masyuk TV, Wang X, Punyashthiti R, Whelan S, Harris PC (2003) Cellular and subcellular localization of the ARPKD
protein; fibrocystin is expressed on primary cilia. Hum Mol Genet 12(20):2703–2710. https://doi.org/10.1093/hmg/ddg274

Wicker LS, Todd JA, Peterson LB (1995) Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol 13:179–200. https://doi.org/10.1146/annurev.iy.13.040195.001143

Williams S, Cobo-Stark P, James L, Somlo S, Igarashi P (2008a) Kidney cysts, pancreatic cysts, and biliary disease in a mouse model of autosomal recessive polycystic kidney disease. Pediatr Nephrol 23(5):733–741. https://doi.org/10.1007/s00467-007-0735-4

Woollard JR, Punyashtiti R, Richardson S, Masyuk TV, Whelan S, Huang BQ, Ward CJ (2007) A mouse model of autosomal recessive polycystic kidney disease with biliary duct and proximal tubule dilatation. Kidney Int 72(3):328–336. https://doi.org/10.1038/sj.ki.5002294

Yang GX, Wu Y, Tsukamoto H, Leung PS, Lian ZX, Rainbow DB, Ridgway WM (2011) CD8 T cells mediate direct biliary ductule damage in nonobese diabetic autoimmune biliary disease. J Immunol 186(2):1259–1267. https://doi.org/10.4049/jimmunol.1001597

Yang Y, Choi J, Chen Y, Invernizzi P, Yang G, Zhang W, Gershwin ME (2022) E. coli and the etiology of human PBC: antimitochondrial antibodies and spreading determinants. Hepatology 75(2):266–279. https://doi.org/10.1002/hep.32172

Zhang MZ, Mai W, Li C (2004) PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells. Proc Natl Acad Sci USA 101:2311–2316. Retrieved from https://doi.org/10.1073/pnas.0400073101

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.